CVR number 37525758
Industry 46.4610 Wholesale of pharmaceutical goods

VasDeBlock medical ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.2% 15.9% 13.2% 23.9% 16.8%  
Credit score (0-100)  16 12 16 3 9  
Credit rating  BB BB BB B BB  
Credit limit (kDKK)  0.0 -0.0 0.0 -0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  17 0 0 0 60  
Gross profit  -32.7 -247 -68.0 -96.7 -56.2  
EBITDA  -32.7 -247 -68.0 -97.1 -56.2  
EBIT  -47.8 -262 -83.2 -112 -56.2  
Pre-tax profit (PTP)  -48.1 -262.9 -83.5 -112.5 -56.2  
Net earnings  -48.1 -262.9 -83.5 -112.5 -56.2  
Pre-tax profit without non-rec. items  -48.1 -263 -83.5 -112 -56.2  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  69.9 74.1 50.5 32.2 70.3  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  75.2 112 50.5 32.2 91.2  
Net Debt  -25.3 -65.4 -16.7 -27.5 -86.9  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  17 0 0 0 60  
Net sales growth  -50.0% -100.0% 0.0% 0.0% 0.0%  
Gross profit  -32.7 -247 -68.0 -96.7 -56.2  
Gross profit growth  2.2% -655.5% 72.5% -42.1% 41.9%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 -0.4 0.0  
Balance sheet total (assets)  75 112 51 32 91  
Balance sheet change%  -34.5% 49.1% -54.9% -36.2% 183.0%  
Added value  -32.7 -247.1 -68.0 -96.7 -56.2  
Added value %  -196.2% 0.0% 0.0% 0.0% -93.7%  
Investments  -30 -30 -30 -30 0  
Net sales trend  -2.0 -3.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  -196.2% 0.0% 0.0% 0.0% -93.7%  
EBIT %  -287.1% 0.0% 0.0% 0.0% -93.7%  
EBIT to gross profit (%)  146.3% 106.1% 122.3% 116.1% 100.0%  
Net Earnings %  -288.4% 0.0% 0.0% 0.0% -93.6%  
Profit before depreciation and extraordinary items %  -197.6% 0.0% 0.0% 0.0% -93.6%  
Pre tax profit less extraordinaries %  -288.4% 0.0% 0.0% 0.0% -93.6%  
ROA %  -50.4% -280.0% -102.3% -271.2% -91.0%  
ROI %  -50.9% -364.3% -133.5% -271.2% -109.6%  
ROE %  -51.2% -365.3% -134.0% -271.8% -109.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  93.0% 66.1% 100.0% 100.0% 77.0%  
Relative indebtedness %  31.6% 0.0% 0.0% 0.0% 35.0%  
Relative net indebtedness %  -120.0% 0.0% 0.0% 0.0% -109.8%  
Net int. bear. debt to EBITDA, %  77.3% 26.5% 24.6% 28.3% 154.5%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  5.6 2.2 0.0 -32,246.0 4.3  
Current Ratio  5.6 2.2 0.0 -32,246.0 4.3  
Cash and cash equivalent  25.3 65.4 16.7 27.5 86.9  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  39.0 56.2 0.0 0.0 65.9  
Current assets / Net sales %  178.5% 0.0% 0.0% 0.0% 152.1%  
Net working capital  24.5 43.8 35.4 32.2 70.3  
Net working capital %  146.9% 0.0% 0.0% 0.0% 117.1%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0